Overview

MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients

Status:
Completed
Trial end date:
2018-04-10
Target enrollment:
Participant gender:
Summary
This is a multi-centre, randomised, double-blind, placebo controlled, parallel group, Phase II study to evaluate efficacy and safety of 3 doses of MEDI7183, in Japanese subjects with moderate to severe UC
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca